Crystal Research Publishes Report on Unigene Laboratories.Business Editors/Health/Medical Writers FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 13, 2003 Crystal Research Associates has published an Executive Informational Overview(TM) (EIO (Enhanced I/O) A hardware interface for HP printers that is used for adding an internal print server and network adapter, a hard disk and other plug-in functionality. EIO cards are smaller than previous MIO cards and more energy efficient. They use the PCI bus. See MIO. (TM)) on Unigene Laboratories Unigene Laboratories (OTC:UGNE) is a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey. , Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : UGNE) outlining extensive details on Unigene's technology, accomplishments, product pipeline and plans for capitalizing on the worldwide osteoporosis market. "Unigene possesses unique technology that is applicable to a large and growing osteoporosis market. Its agreements with GlaxoSmithKline PLC and Upsher Smith Laboratories help validate the technology and affirm the value of this market," said Jeffrey J. Kraws, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Co-Founder of Crystal Research Associates. "At Crystal Research Associates, we continue to focus on conveying clear and accurate representations of companies' stories to the investment community, vis-a-vis our 'Facts Without Fiction' model, using our expertise in writing EIOs(TM)." The EIO, entitled "Peptide-Focused Biopharmaceutical Opportunity," is available and either an electronic or a hard copy can be obtained by contacting the Investor Relations Investor relations The process by which the corporation communicates with its investors. Group at (212) 825-3210 or Crystal Research at (609) 395-7626. About Unigene Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin calcitonin /cal·ci·to·nin/ (-to´nin) a polypeptide hormone secreted by C cells of the thyroid gland, and sometimes of the thymus and parathyroids, which lowers calcium and phosphate concentration in plasma and inhibits bone resorption. and PTH-based therapies. Unigene has licensed the U.S. rights for Fortical(R), its nasal calcitonin product, to Upsher-Smith Laboratories and the worldwide rights for its oral PTH PTH abbr. parathyroid hormone Parathyroid hormone (PTH) A chemical substance produced by the parathyroid glands. This hormone is a major element in regulating calcium in the body. technology to GlaxoSmithKline. The U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. is currently reviewing Unigene's new drug application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for Fortical. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. About Crystal Research Associates Crystal Research Associates is an independent research service firm dedicated to helping companies achieve their goals through consultancy services and increasing their visibility by publishing Executive Informational Overviews(TM) (EIOs(TM)). More information on Crystal Research Associates is available at www.crystalresearchassociates.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion